These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 18369019

  • 1. Cytomegalovirus infection in paediatric haemopoietic stem cell transplantation.
    Chong AL, Clinton F, Breatnach F, O'Marcaigh A, Butler K, O'Meara A.
    Ir Med J; 2008 Jan; 101(1):17-21. PubMed ID: 18369019
    [Abstract] [Full Text] [Related]

  • 2. High-dose acyclovir and pre-emptive ganciclovir in prevention of cytomegalovirus disease in pediatric patients following peripheral blood stem cell transplantation.
    Hazar V, Kansoy S, Küpesiz A, Aksoylar S, Kantar M, Yeşilipek A.
    Bone Marrow Transplant; 2004 May; 33(9):931-5. PubMed ID: 15034541
    [Abstract] [Full Text] [Related]

  • 3. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B, Pati N, Gilroy N, Ratnamohan M, Huang G, Kerridge I, Hertzberg M, Gottlieb D, Bradstock K.
    Transpl Infect Dis; 2010 Aug 01; 12(4):322-9. PubMed ID: 20487414
    [Abstract] [Full Text] [Related]

  • 4. Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study.
    Moretti S, Zikos P, Van Lint MT, Tedone E, Occhini D, Gualandi F, Lamparelli T, Mordini N, Berisso G, Bregante S, Bruno B, Bacigalupo A.
    Bone Marrow Transplant; 1998 Jul 01; 22(2):175-80. PubMed ID: 9707026
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients.
    Shereck EB, Cooney E, van de Ven C, Della-Lotta P, Cairo MS.
    Pediatr Blood Cancer; 2007 Sep 01; 49(3):306-12. PubMed ID: 16972242
    [Abstract] [Full Text] [Related]

  • 8. Cytomegalovirus antigenemia and outcomes of patients undergoing allogeneic peripheral blood stem cell transplantation: effects of long-term high-dose acyclovir prophylaxis and preemptive ganciclovir treatment.
    Hazar V, Ugur A, Colak D, Saba R, Tezcan G, Kupesiz A, Karadogan I, Gultekin M, Yesilipek A, Undar L.
    Jpn J Infect Dis; 2006 Aug 01; 59(4):216-21. PubMed ID: 16936338
    [Abstract] [Full Text] [Related]

  • 9. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
    Burns LJ, Miller W, Kandaswamy C, DeFor TE, MacMillan ML, Van Burik JA, Weisdorf DJ.
    Bone Marrow Transplant; 2002 Dec 01; 30(12):945-51. PubMed ID: 12476289
    [Abstract] [Full Text] [Related]

  • 10. Cytomegalovirus infection after allogeneic stem cell transplant in children.
    Haastrup E, Müller K, Baekgaard H, Heilmann C.
    Pediatr Transplant; 2005 Dec 01; 9(6):734-40. PubMed ID: 16269044
    [Abstract] [Full Text] [Related]

  • 11. Cytomegalovirus pp65 antigenemia-guided pre-emptive treatment with ganciclovir after allogeneic stem transplantation: a single-center experience.
    Manteiga R, Martino R, Sureda A, Labeaga R, Brunet S, Sierra J, Rabella N.
    Bone Marrow Transplant; 1998 Nov 01; 22(9):899-904. PubMed ID: 9827819
    [Abstract] [Full Text] [Related]

  • 12. [Cytomegalovirus diseases after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) and related risk factors].
    Huang XJ, Xu LP, Ren HY, Zhang YC, Guo NL, Lu DP.
    Zhonghua Yi Xue Za Zhi; 2003 May 10; 83(9):766-9. PubMed ID: 12899755
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Valacyclovir for the prevention of cytomegalovirus infection after allogeneic stem cell transplantation: a single institution retrospective cohort analysis.
    Vusirikala M, Wolff SN, Stein RS, Brandt SJ, Morgan DS, Greer JP, Schuening FG, Dummer JS, Goodman SA.
    Bone Marrow Transplant; 2001 Aug 10; 28(3):265-70. PubMed ID: 11535994
    [Abstract] [Full Text] [Related]

  • 17. Risk factors for late cytomegalovirus infection after allogeneic stem cell transplantation using HLA-matched sibling donor: donor lymphocyte infusion and previous history of early CMV infection.
    Kim DH, Kim JG, Lee NY, Sung WJ, Sohn SK, Suh JS, Lee KS, Lee KB.
    Bone Marrow Transplant; 2004 Jul 10; 34(1):21-7. PubMed ID: 15133483
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Treatment of refractory CMV-infection following hematopoietic stem cell transplantation with the combination of foscarnet and leflunomide.
    Ehlert K, Groll AH, Kuehn J, Vormoor J.
    Klin Padiatr; 2006 Jul 10; 218(3):180-4. PubMed ID: 16688677
    [Abstract] [Full Text] [Related]

  • 20. Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation.
    Almyroudis NG, Jakubowski A, Jaffe D, Sepkowitz K, Pamer E, O'Reilly RJ, Papanicolaou GA.
    Transpl Infect Dis; 2007 Dec 10; 9(4):286-94. PubMed ID: 17511819
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.